Systematic Review of Efficacy and Safety of Oral Chinese Patent Medicine in the Treatment of Adult Cough Variant Asthma

WANG Lin; XU Guanglan; WANG Guangyao; PENG Simin; ZHANG Yanyan; PEI Kai; HONG Mei

doi:10.14009/j.issn.1672-2124.2023.01.017

您当前的位置：

首页 >

文章列表页 >

Systematic Review of Efficacy and Safety of Oral Chinese Patent Medicine in the Treatment of Adult Cough Variant Asthma

更新时间：2023-04-14

- Systematic Review of Efficacy and Safety of Oral Chinese Patent Medicine in the Treatment of Adult Cough Variant Asthma
- Issue 1, Pages: 80-87(2023)
- 作者机构：
  
  1. 广西中医药大学研究生院
  2. 广西中医药大学第一附属医院呼吸与危重症医学科
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2023.01.017
  CLC： R256.1
- Published：2023，
扫描看全文
WANG Lin, XU Guanglan, WANG Guangyao, et al. Systematic Review of Efficacy and Safety of Oral Chinese Patent Medicine in the Treatment of Adult Cough Variant Asthma. [J]. (1):80-87(2023)
DOI：

WANG Lin, XU Guanglan, WANG Guangyao, et al. Systematic Review of Efficacy and Safety of Oral Chinese Patent Medicine in the Treatment of Adult Cough Variant Asthma. [J]. (1):80-87(2023) DOI： 10.14009/j.issn.1672-2124.2023.01.017.

摘要

目的：系统评价口服中成药联合常规西药治疗成人咳嗽变异性哮喘（CVA）的有效性和安全性。方法：计算机检索中国知网、万方数据库、维普数据库、中国生物医学文献数据库、PubMed、Embase和the Cochrane Library等数据库，检索时间均为建库至2022年1月。检索口服中成药联合常规西药治疗成人CVA的临床随机对照试验，严格按照纳入与排除标准进行文献筛选。采用NoteExpress 3.5、Excel软件进行资料提取，采用RevMan 5.4软件进行文献质量评价及统计学分析。结果：最终纳入35篇文献，合计2 947例CVA患者。Meta分析结果显示，相较于常规西药治疗，口服中成药联合常规西药治疗在提高临床总有效率（RR=1.21

95%CI=1.16～1.25

P＜0.000 01）、第1秒用力呼气容积（SMD=1.59

95%CI=1.17～2.01

P＜0.000 01）、用力肺活量（SMD=1.58

95%CI=0.99～2.18

P＜0.000 01）、第1秒用力呼气容积/用力肺活量（SMD=1.29

95%CI=0.65～1.94

P＜0.000 1）和呼气流量峰值（SMD=1.00

95%CI=0.65～1.36

P＜0.000 01）等方面疗效显著，在降低白细胞介素4（SMD=-1.56

95%CI=-2.47～-0.64

P=0.000 8）、白细胞介素6（SMD=-1.83

95%CI=-2.50～-1.16

P＜0.000 01）、肿瘤坏死因子α（SMD=-1.72

95%CI=-2.11～-1.34

P＜0.000 01）和嗜酸性粒细胞（SMD=-1.35

95%CI=-1.78～-0.92

P＜0.000 01）等指标水平方面具有一定优势，并能有效改善咳嗽症状积分（日间咳嗽症状积分：SMD=-2.07

95%CI=-3.07～-1.07

P＜0.000 1;夜间咳嗽症状积分：SMD=-2.26

95%CI=-3.39～-1.12

P＜0.000 1）

且不良反应发生率较低（RR=0.55

95%CI=0.33～0.93

P=0.03）

上述差异均有统计学意义。结论：在常规西药治疗基础上联合口服中成药治疗成人CVA患者具有良好的临床疗效，且安全性较高，但由于纳入的文献质量、数量有限，未来仍需更大规模的随机对照试验加以验证。

Abstract

OBJECTIVE: To systematically evaluate the efficacy and safety of oral Chinese patent medicine combined with conventional western medicine in the treatment of adult cough variant asthma（CVA）. METHODS: CNKI

Wanfang Data

VIP

CBM

PubMed

Embase

and the Cochrane Library were retrieved to collect the clinical randomized controlled trial of oral Chinese patent medicine combined with conventional western medicine in the treatment of adult CVA

the retrieval time was from the establishment of the database to Jan. 2022. Literature was screened strictly according to the inclusion and exclusion criteria. NoteExpress 3.5 and Excel software were used for data extraction

and RevMan 5.4 software was used for literature quality evaluation and statistical analysis. RESULTS: A total of 35 articles were enrolled

including 2 947 patients with CVA. Meta-analysis showed that compared with conventional western medicine treatment

oral Chinese patent medicine combined with conventional western medicine had significant efficacy in improving the total clinical efficiency（RR=1.21

95%CI=1.16-1.25

P<0.000 01）

forced expiratory volume in one second（SMD=1.59

95%CI=1.17-2.01

P<0.000 01）

forced vital capacity（SMD=1.58

95%CI=0.99-2.18

P<0.000 01）

forced expiratory volume in one second/forced vital capacity（SMD=1.29

95%CI=0.65-1.94

P<0.000 1） and peak expiratory flow（SMD=1.00

95%CI=0.65-1.36

P<0.000 01）

had advantages in reducing levels of interleukin-4（SMD=-1.56

95%CI=-2.47--0.64

P=0.000 8）

interleukin-6（SMD=-1.83

95%CI=-2.50--1.16

P<0.000 01）

tumor necrosis factor-α（SMD=-1.72

95%CI=-2.11--1.34

P<0.000 01） and eosinophils（SMD=-1.35

95%CI=-1.78--0.92

P<0.000 01）

and could effectively improve the cough symptom score（daytime cough symptom score: SMD=-2.07

95%CI=-3.07--1.07

P<0.000 1; nocturnal cough symptom score: SMD=-2.26

95%CI=-3.39--1.12

P<0.000 1） with lower incidence of adverse drug reactions（RR=0.55

95%CI=0.33-0.93

P=0.03）

the differences were statistically significant. CONCLUSIONS: The clinical efficacy of oral Chinese patent medicine combined with conventional western medicine in the treatment of adult CVA is significant with higher safety. However

due to the limited quality and quantity of the included literature

larger scale randomized controlled trials are still needed to verify it in the future.

关键词

中成药成人咳嗽变异性哮喘Meta分析

Keywords

Chinese patent medicineAdultCough variant asthmaMeta-analysis

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Systematic Review of Huisheng Oral Liquid on Coagulation Function, Efficacy and Safety of Patients with Non-Small Cell Lung Cancer

Systematic Review of Efficacy and Safety of Dantian Jiangzhi Pills Combined with Statins in the Treatment of Hyperlipidemia

Analysis of Clinical Status of Guiding Herbs for Chinese Patent Medicine Included in Chinese Pharmacopoeia （Part Ⅰ）

Systematic Review of Clinical Efficacy and Safety of Formula Granules of Liangfu Pill in the Treatment of Epigastric Pain

Systematic Review of Runzao Zhiyang Capsules Combined with Antihistamine in the Treatment of Chronic Urticaria

Related Author

ZHANG Jinhua

TIAN Yuan

YANG Xiaoping

ZHANG Yi

LIU Wei

LI Xingxing

FAN Zongjing

CUI Jie

Related Institution

Dept. of Oncology, Jingmen First People’s Hospital

Traditional Chinese Medicine Phenomics Research Center, Traditional Chinese Medicine Hospital Affiliated to Southwest Medical University

Dept. of Internal Medicine of Traditional Chinese Medicine, Shanghai Seventh People’s Hospital

Dept. of Internal Medicine of Traditional Chinese Medicine, Shanghai Tongren Hospital

Second School of Clinical Medicine, Beijing University of Chinese Medicine

⁰